219 related articles for article (PubMed ID: 34285919)
41. Bioinformatics analysis of the role of CXC ligands in the microenvironment of head and neck tumor.
Jing F; Wang J; Zhou L; Ning Y; Xu S; Zhu Y
Aging (Albany NY); 2021 Jul; 13(13):17789-17817. PubMed ID: 34247149
[TBL] [Abstract][Full Text] [Related]
42. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma.
Takahashi H; Kawabata-Iwakawa R; Ida S; Mito I; Tada H; Chikamatsu K
Sci Rep; 2021 Sep; 11(1):17789. PubMed ID: 34493792
[TBL] [Abstract][Full Text] [Related]
43. A Five-mRNA Expression Signature to Predict Survival in Oral Squamous Cell Carcinoma by Integrated Bioinformatic Analyses.
Guo H; Li C; Su X; Huang X
Genet Test Mol Biomarkers; 2021 Aug; 25(8):517-527. PubMed ID: 34406843
[No Abstract] [Full Text] [Related]
44. Identification of SLC2A3 as a prognostic indicator correlated with the NF-κB/EMT axis and immune response in head and neck squamous cell carcinoma.
Chai F; Zhang J; Fu T; Jiang P; Huang Y; Wang L; Yan S; Yan X; Yu L; Xu Z; Wang R; Xu B; Du X; Jiang Y; Zhang J
Channels (Austin); 2023 Dec; 17(1):2208928. PubMed ID: 37134043
[TBL] [Abstract][Full Text] [Related]
45. Establishment of an immune-related gene prognostic model for head and neck tumors.
Zhou F; Chen AX; Lv HY; Liang DH; Yu HS
J Biol Regul Homeost Agents; 2021; 35(3):975-986. PubMed ID: 34159769
[TBL] [Abstract][Full Text] [Related]
46. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma.
Li Y; Liu H
Cancer Biomark; 2022; 34(3):359-374. PubMed ID: 35068446
[TBL] [Abstract][Full Text] [Related]
47. An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.
Chen Y; Li ZY; Zhou GQ; Sun Y
Clin Cancer Res; 2021 Jan; 27(1):330-341. PubMed ID: 33097495
[TBL] [Abstract][Full Text] [Related]
48. Overexpression of XRCC1 is Associated with Poor Survival in Patients with Head and Neck Squamous Carcinoma and Has Potential to Be Used as Targeted Therapy by Synthetic Lethality.
Ahirwar SS; Lasunte S; Gupta M; Chowdhary R; Kotnis A
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3525-3535. PubMed ID: 37898859
[TBL] [Abstract][Full Text] [Related]
49. Comprehensive analysis of the prognosis and biological significance of ROR
Zheng J; Tang H; Yang Y; Yang K
Environ Toxicol; 2024 Feb; 39(2):487-508. PubMed ID: 37278231
[TBL] [Abstract][Full Text] [Related]
50. Co-expression network-based identification of biomarkers correlated with the lymph node metastasis of patients with head and neck squamous cell carcinoma.
Jin Y; Qin X
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32076707
[TBL] [Abstract][Full Text] [Related]
51. Expression and gene regulation network of INHBA in Head and neck squamous cell carcinoma based on data mining.
Wu ZH; Tang Y; Niu X; Cheng Q
Sci Rep; 2019 Oct; 9(1):14341. PubMed ID: 31586103
[TBL] [Abstract][Full Text] [Related]
52. FSCN1 is upregulated by SNAI2 and promotes epithelial to mesenchymal transition in head and neck squamous cell carcinoma.
Wang L; Jia Y; Jiang Z; Gao W; Wang B
Cell Biol Int; 2017 Aug; 41(8):833-841. PubMed ID: 28488774
[TBL] [Abstract][Full Text] [Related]
53. MYO5A overexpression promotes invasion and correlates with low lymphocyte infiltration in head and neck squamous carcinoma.
Xing J; Gu Y; Song Y; Liu Q; Chen Q; Han P; Shen Z; Li H; Zhang S; Bai Y; Ma J; Sui F
BMC Cancer; 2023 Dec; 23(1):1267. PubMed ID: 38129784
[TBL] [Abstract][Full Text] [Related]
54. IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma.
Hu Y; Chen J; Liu M; Feng Q; Peng H
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281789
[TBL] [Abstract][Full Text] [Related]
55. A Signature of N
Chen J; Lu T; Zhong F; Lv Q; Fang M; Tu Z; Ji Y; Li J; Gong X
Front Immunol; 2022; 13():809872. PubMed ID: 35185897
[TBL] [Abstract][Full Text] [Related]
56. Bioinformatic analysis of PFN2 dysregulation and its prognostic value in head and neck squamous carcinoma.
Liu J; Wu Y; Wang Q; Liu X; Liao X; Pan J
Future Oncol; 2018 Feb; 14(5):449-459. PubMed ID: 29322815
[TBL] [Abstract][Full Text] [Related]
57. The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes T; Melchardt T; Hufnagl C; Weiss L; Mittermair C; Neureiter D; Klieser E; Rinnerthaler G; Roesch S; Gaggl A; Greil R; Egle A
Pharmacogenomics J; 2018 May; 18(3):474-479. PubMed ID: 28719596
[TBL] [Abstract][Full Text] [Related]
58. Peroxisome proliferator-activated receptors signature reveal the head and neck squamous cell carcinoma energy metabolism phenotype and clinical outcome.
Yao Y; Wang D; Zhang Y; Tang Q; Xu Z; Qin L; Qu Y; Yan Z
J Gene Med; 2024 Jan; 26(1):e3605. PubMed ID: 37932968
[TBL] [Abstract][Full Text] [Related]
59. Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer.
Feng B; Shen Y; Pastor Hostench X; Bieg M; Plath M; Ishaque N; Eils R; Freier K; Weichert W; Zaoui K; Hess J
Clin Cancer Res; 2020 Jul; 26(14):3616-3628. PubMed ID: 32161122
[TBL] [Abstract][Full Text] [Related]
60. The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma.
He L; Ren D; Lv G; Mao B; Wu L; Liu X; Gong L; Liu P
Cancer Med; 2023 Jan; 12(1):852-861. PubMed ID: 35621268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
